Home
Drugs
Bendamustine
Clinical Trials

Clinical Trials Related to Bendamustine

Related studies linked through entity extraction aliases.

A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma

Status: COMPLETED
Phase: PHASE3

A Phase II Study for Patients With Indolent Non-follicular Non-Hodgkin's Lymphoma

Status: COMPLETED
Phase: PHASE2

A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia

Status: COMPLETED
Phase: PHASE3

Bendamustine Hydrochloride, Clofarabine, and Etoposide in Treating Younger Patients With Relapsed or Refractory Hematologic Malignancies

Status: COMPLETED
Phase: PHASE1

Capecitabine + Bendamustine in Women With Pretreated Locally Advanced or Metastatic Her2-negative Breast Cancer

Status: COMPLETED
Phase: PHASE2

A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL)

Status: COMPLETED
Phase: PHASE3

Bendamustine, Gemcitabine and Vinorelbine (BeGEV) as Induction Therapy in Relapsed/Refractory Hodgkin's Lymphoma Patients

Status: UNKNOWN
Phase: PHASE2

Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma

Status: COMPLETED
Phase: PHASE1/PHASE2

Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies

Status: COMPLETED
Phase: PHASE1

BR in Patients With CLL With Comorbidities and/or Renal Dysfunction

Status: COMPLETED
Phase: PHASE1

A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma

Status: COMPLETED
Phase: PHASE3

Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLL

Status: COMPLETED
Phase: PHASE2

Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE1/PHASE2

Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas

Status: TERMINATED
Phase: PHASE3

A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a

Status: COMPLETED
Phase: PHASE3

A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)

Status: COMPLETED
Phase: PHASE2

Bendamustine, Lenalidomide (Revlimid®) and Dexamethasone (BRd) as 2nd-line Therapy for Patients With Relapsed or Refractory Multiple Myeloma

Status: COMPLETED
Phase: PHASE2

Drug-drug Interaction Study of Ofatumumab With Bendamustine in Subjects With Indolent B-cell Non-Hodgkin's Lymphoma

Status: COMPLETED
Phase: PHASE1

Study of Bendamustine, Lenalidomide and Low-dose Dexamethasone, for the Treatment of Patients With Relapsed Myeloma

Status: UNKNOWN
Phase: PHASE1/PHASE2

A Trial Looking at Ofatumumab for People With Chronic Lymphocytic Leukaemia Who Cannot Have More Intensive Treatment

Status: UNKNOWN
Phase: PHASE3